| Title: |
Factor XII and prekallikrein promote microvascular inflammation and psoriasis in mice. |
| Authors: |
Zhang, Yurong1 (AUTHOR), Chen, Zengrong1 (AUTHOR), Guo, Junyan1,2 (AUTHOR), Wan, Qing1 (AUTHOR), Zhang, Yingjie1 (AUTHOR), Li, Huihui1 (AUTHOR), Rao, Haojie1 (AUTHOR), Yang, Jianfeng1 (AUTHOR), Xu, Pengfei1 (AUTHOR) pfeixu@163.com, Chen, Hong1 (AUTHOR) chen-paper@outlook.com, Wang, Miao1,3,4 (AUTHOR) miao.wang@pumc.edu.cn |
| Source: |
British Journal of Pharmacology. Oct2024, Vol. 181 Issue 19, p3760-3778. 19p. |
| Subject Terms: |
*LASER Doppler velocimeter, *BRADYKININ receptors, *CONTACT inhibition, *BRADYKININ, *SKIN diseases |
| Abstract: |
Background and Purpose: Psoriasis is an autoimmune inflammatory skin disease, featuring microvascular abnormalities and elevated levels of bradykinin. Contact activation of Factor XII can initiate the plasma kallikrein‐kinin cascade, producing inflammation and angioedema. The role of Factor XII in psoriasis is unknown. Experimental Approach: The effects of deficiency of Factor XII or its enzymatic substrate, prekallikrein, were examined in the imiquimod‐induced mouse model of psoriasis. Skin microcirculation was assessed using intravital confocal microscopy and laser Doppler flowmeter. A novel antibody blocking Factor XII activation was evaluated for psoriasis prevention. Key Results: Expression of Factor XII was markedly up‐regulated in human and mouse psoriatic skin. Genetic deletion of Factor XII or prekallikrein, attenuated imiquimod‐induced psoriatic lesions in mice. Psoriatic induction increased skin microvascular blood perfusion, causing vasodilation, hyperpermeability and angiogenesis. It also promoted neutrophil‐vascular interaction, inflammatory cytokine release and enhanced Factor XII / prekallikrein enzymatic activity with elevated bradykinin. Factor XII or prekallikrein deficiency ameliorated these microvascular abnormalities and abolished bradykinin increase. Antagonism of bradykinin B2 receptors reproduced the microvascular protection of Factor XII / prekallikrein deficiency, attenuated psoriatic lesions, and prevented protection by Factor XII / prekallikrein deficiency against psoriasis. Furthermore, treatment of mice with Factor XII antibody alleviated experimentally induced psoriasis and suppressed microvascular inflammation. Conclusion and Implications: Activation of Factor XII promoted psoriasis via prekallikrein‐dependent formation of bradykinin, which critically mediated psoriatic microvascular inflammation. Inhibition of contact activation represents a novel therapeutic strategy for psoriasis. [ABSTRACT FROM AUTHOR] |
|
Copyright of British Journal of Pharmacology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
